Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calistoga Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Formed around a preclinical program licensed from Icos, Calistoga Pharmaceuticals Inc. is developing multiple small-molecule inhibitors of the phosphoinositide-3 kinase pathway, a hot area in inflammation. Calistoga is targeting the PI3K delta isoform. Its initial clinical indications are hematological malignancies, asthma, and rheumatoid arthritis. A Phase I trial of CAL-101, an orally available, small-molecule inhibitor for inflammatory disease and cancer, is currently underway.

You may also be interested in...



It's Apples Versus Oranges in the PI3 Kinase Race

Someone seeking a clinical space that offers a great deal of activity and anticipation, and where the major developments and dealmaking remain around the corner, would have to look no further than the PI3 kinase area. Early bets placed on PI3K pan-selective inhibitors may pay off, but smart money lately has been focused on isoform-selective inhibition of this signaling pathway implicated in cancer, inflammation, and autoimmune disease. In this issue, we profile three emerging companies hoping to succeed in developing PI3K inhibitors for diverse clinical applications: Arno Therapeutics, Intellikine, and Paloma Pharmaceuticals.

It's Apples Versus Oranges in the PI3 Kinase Race

Someone seeking a clinical space that offers a great deal of activity and anticipation, and where the major developments and dealmaking remain around the corner, would have to look no further than the PI3 kinase area. Early bets placed on PI3K pan-selective inhibitors may pay off, but smart money lately has been focused on isoform-selective inhibition of this signaling pathway implicated in cancer, inflammation, and autoimmune disease. In this issue, we profile three emerging companies hoping to succeed in developing PI3K inhibitors for diverse clinical applications: Arno Therapeutics, Intellikine, and Paloma Pharmaceuticals.

Start-Ups Against Inflammation

Inflammation plays a part in a wide range of diseases across a broad spectrum of markets, including the huge and already crowded, like rheumatoid arthritis; the difficult to navigate, like Crohn's disease; and the emerging, like atherosclerosis. Start-ups looking to compete in inflammation can boost their chances of success by focusing on niche indications or on drug targets with broad applicability, and thus attract the attention of in-licensers or acquirers. In this issue, we profile four young companies hoping to prove the worth of their technologies to investors and partners alike.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel